DIABETES MELLITUS E A DOENÇA DE ALZHEIMER
Palavras-chave:
Demência. Encéfalo. InsulinaResumo
A associação entre a Diabete Mellitus e a demência está sendo alvo de forte interesse devido a alta incidência com o aumento da expectativa de vida. A diabete, assim como doenças vasculares, apresenta forte fator de risco para o desenvolvimento de demências. Muitos fatores afetam adversamente a saúde do cérebro de indivíduos com Diabetes, incluindo a desregulação energética, inflamação, diminuição da perfusão, aumento do estresse oxidativo e deposição proteica. A diabete é uma doença metabólica complexa que pode ter efeitos devastadores sobre múltiplos sistemas orgânicos. É proposto que na fisiopatologia do déficit cognitivo no diabético sejam pela hipoglicemia crônica, efeitos acumulativos de eventos hipoglicêmicos e possíveis efeitos diretos da insulina no sistema nervoso central. Ainda não está claro se esses fatores, isoladamente, ou, em conjunto, conduzem ao desenvolvimento do déficit cognitivo. Fortes evidências demonstram que a Doença de Alzheimer, juntamente com as doenças cardiovasculares e diabetes possam ter uma mesma origem. Tendo em vista a discussão que o metabolismo energético seja enfatizado devido à hipoperfusão, não é difícil especular que a Diabetes possa ser um componente importante na patogênese da Doença de Alzheimer por reflexo da vasculopatia associada, resultando em danos ao ambiente microvascular. Com base nesta revisão foi possível perceber a forte a fluência da Diabetes sobre o quadro de declínio cognitivo o que sugere uma forte influência da Diabetes no desenvolvimento da Doença de Alzheimer e a existência de um potencial link etiológico entre as Doenças Vasculares, Diabetes e a Doença de Alzheimer.Referências
Kumar R, Looi JC, Raphael B. 2009. Type 2 diabete mellitus, cognition brain and aging: A brief review. Indian, psychiatry supplement, January 2009.
Espeland MA, Bryan RN, Goveas JS. et al. Influence of Type 2 Diabetes on Brain Volumes and Changes in Brain Volumes Results from the Women’s Health Initiative Magnetic Resonance Imaging Studies. E p i d e m i o l o g y / H e a l t h S e r v i c e s R e s e a r c h DIABETES CARE, VOLUME 36, JANUARY 2013.
Awad N, Gagnon M, Messier C. et al. The relationship between impaired glucose tolerance, type 2 diabetes and cognitive function. J Clinc Exp Neuropshycol 2004.
Hwang J, Choi CS. Use of in vivo magnetic resonance spectroscopy for studying metabolic diseases. Experimental & Molecular Medicine (2015) 47, e139.
Ryan John.P. Fine, D.F. Rosano, C. Type 2 diabetes and cognitive impairment: contributions from neuroimaging. J Geriatr Psychiatry Neurol 2014; 27: 47-55 [PMID: 24394151.
Kodl CT, Franc DT, Rao JP, Anderson FS. et al. Diffusion Tensor Imaging Identifies Deficits in White Matter Microstructure in Subjects With Type 1 Diabetes That Correlate With Reduced Neurocognitive Function. DIABETES, VOL. 57, NOVEMBER 2008.
Morabito MV, Berman DE, Schneider RT. et al. Hyperleucinemia causes hippocampal retromer deficiency linking diabetes to Alzheimer's disease. Neurobiol Dis. 2014 May;65:188-92.
Mccall, A. L. The Impact of Diabetes on the CNS. Diabetes. 1992; 41:557–570.
Stevens MJ, Lattimer SA, Kamijo M. et al. Osmotically-Induced Nerve Taurine Depletion and the Compatible Osmolyte Hypothesis in Experimental Diabetic Neuropathy in the Rat. Diabetologia. 1993; 36:608–614.
Nurjhan N, Ktorza A, Ferre P. et al. Effects of gestational hyperglycemia on glucose metabolism and its hormonal control in the fasted, newborn rat during the early postnatal period. Diabetes. 1985; 34:995–1001. Neurosci Biobehav Rev. 2007; 31(7):1046–1063.
Duelli R, Maurer MH, Staudt R. et al. Increased cerebral glucose utilization and decreased glucose transporter GLUT1 during chronic hyperglycemia in rat brain. Brain Res. 2000; 858:338–347.
Sharma R, Buras E, Terashima T. et al. Hyperglycemia induces oxidative stress and impairs axonal transport rates in mice. PLoS One. 2010; 5:e13463.
Balasseeo, Fery F. Ketone body production and disposal: effects of fasting, diabetes, and exercise. Diabetes Metab Rev. 1989; 5:247–270.
Yan SD, Chen X, Fu J. et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature 382, 685–691 (1996).
Takeda S, Sato N, Uchio-Yamada K. et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci USA 107, 7036–7041 (2010).
Craft S, Montine TJ, Minoshima S. et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69, 29–38 (2012).
Macauley SL, Stanley M, Caesar EE. et al. Hyperglycemia modulates extracellular amyloid-beta concentrations and neuronal activity in vivo. J Clin Invest 125, 2463–2467 (2015).
Guo C, Zhang S, Li JY. et al. Chronic hyperglycemia induced via the heterozygous knockout of Pdx1 worsens neuropathological lesion in an Alzheimer mouse model. Sci Rep. 2016 Jul 12;6:29396.
Craf S, Watson SG. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Nurol 2004.
Oddo S, Caccamo A, Shepherd JD. et al. Triple trangenic modelo f Alzheimer’s disese with plaques and angle: intracellular A? and synaptic dysfunction. Neuron 2003.
Chobanian AV. The seventh report of the Joint National Committee on prevention, detection, eval¬uation, and treatment of high blood pressure: the JNC 7 report. JAMA 289: 2560 2572, 2003.
Cao Z, Ye BD, Shen ZW, et al. 2D-H proton magnetic resonance spectroscopic imaging study on brain metabolite alterations in patients with diabetic hypertension. MOLECULAR MEDICINE REPORTS 11: 4232-4238, 2015.
Cole AR, Astell A, Green C. et al. Molecular connexions between dementia and diabetes.
Torre JC. Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer's disease. Ann N Y Acad Sci. 2000;924:136-52.
Helena A, Chui C. Clinical and imaging features of mixed Alzheimer and vascular pathologies. Alzheimer's Research & Therapy (2015) 7:21.
Wang F, Guo X, Shen X. et al. Vascular Dysfunction Associated with Type 2 Diabetes and Alzheimer’s Disease: A Potential Etiological Linkage. Med Sci Monit Basic Res, 2014; 20: 118-129.
Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 2008 Nov;2(6):1101-13.
Talbot K, Wang HY, Kazi H. et al. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012; 122:1316–1338.
Hirosumi J, Tuncman G, Chang L. et al. A central role for JNK in obesity and insulin resistance. Nature 2010;420:333–336.
Yarchoan M, Arnold E. Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Diseas Diabetes 2014;63:2253–2261. Arnold2,3. Diabetes Volume 63, July 2014.
Xie L, Helmerhorst E, Taddei K. et al. Alzheimer’s beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 2002;22:RC221.
Kim DY, Jung SY, Kim. K. et al. Treadmill exercise ameliorates Alzheimer disease-associated memory loss through the Wnt signaling pathway in the streptozotocin-induced diabetic rats. J Exerc Rehabil. 2016 Aug 31;12(4):276-83.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2018 Arquivos Catarinenses de Medicina
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
